Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Cosmetic – antiperspirant – dentifrice
Reexamination Certificate
2001-03-07
2003-01-14
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Cosmetic, antiperspirant, dentifrice
C424S405000, C424S078060, C424S601000, C424S464000, C424S499000, C514S859000, C514S928000
Reexamination Certificate
active
06506393
ABSTRACT:
DESCRIPTION
The present invention concerns a process for the production of a pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis.
Leishmaniasis is a name for various tropical diseases which are caused by flagellates of the genus Leishmania and is transmitted by various blood-sucking insects. The manifestations of leishmaniasis may be visceral (kala-azar), mucocutaneous (american leishmaniasis) or cutaneous (Aleppo boil or diffuse cutaneous leishmaniasis). The incubation period is weeks or months. A very high mortality rate is observed in untreated cases, in particular with kala-azar and american leishmaniasis.
The therapeutic agents used today for the treatment of leishmaniasis are pentavalent antimony compounds (e.g. sodium stibogluconate) and aromatic diamidines. A disadvantage of these drugs is, however, that they cause severe side-effects such as nausea and vomitting due to their high toxicity. Moreover there are already Leishmania strains which are resistant to antimony.
Croft et al (Biochem. Pharmacol. 36 (1987), p. 2633-2636) describe experiments in which the effectiveness of alkyl phosphocholines against Leishmania donovani was investigated. The effect of alkyl phosphocholines was tested in comparison with the effect of the standard therapeutic preparation, sodium stibogluconate, (Pentostam) when administered subcutaneously. In this process it was found that alkyl phosphocholines, in particular C
22
alkyl phosphocholines are active against Leishmania. It was, however, also established that the alkyl phosphocholines, in particular hexadecyl-phosphocholine, were highly toxic for the experimental animals, in particular for macrophages in therapeutically effective doses so that they do not represent a real alternative when administered subcutaneously to the known therapy with sodium stibogluconate.
Thus the object of the present invention was to provide a pharmaceutical agent for protozoal diseases, in particular for leishmaniasis, in which the disadvantages of the state of the art, in particular with regard to the severe side-effects, are at least partially eliminated.
The object according to the present invention is achieved by a process for the production of a pharmaceutical agent for oral or topical administration in the treatment of protozoal diseases, in particular of leishmaniasis, which contains as the active substance one or several compounds having the general formula I
in which R
1
is a saturated or monounsaturated or polyunsaturated hydrocarbon residue with 12 to 20 C atoms and R
2
, R
3
and R
4
denote independently of one another hydrogen, a C
1
-C
5
alkyl group, a C
3
-C
6
cycloalkyl group or a C
1
-C
5
hydroxyalkyl group whereby two of the residues R
2
, R
3
and R
4
can together form a C
2
-C
5
alkylene group which, if desired, can be substituted with an —O—, —S— or NR
5
group, in which R
5
is hydrogen, a C
1
-C
5
alkyl group, a C
3
-C
6
cycloalkyl group or a C
1
-C
5
hydroxyalkyl group as well as, if desired the usual pharmaceutical auxiliary, diluting, carrier or/and filling substances.
In the general formula I, R
1
can be branched or straight-chained. R
1
is preferably a straight-chained hydrocarbon residue with 16 to 20 C atoms, in particular a hexadecyl, octadecyl, oleyl, elaidyl, eicosyl or eicosenyl-cis-(&ohgr;-9) residue. R
1
is particularly preferably a hexadecyl or octadecyl residue.
Examples of suitable residues R
2
, R
3
and R
4
in the formula I are for instance methyl, ethyl, propyl, butyl and pentyl residues, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl residues, hydroxymethyl, hydroxyethyl and hydroxypropyl residues. Two of the residues R
2
, R
3
and R
4
can for example form a pyrrolidine, a piperidine or a morpholine group. At least one of the residues R
2
, R
3
and R
4
is preferably different from hydrogen, it is particularly preferred that all 3 residues are different from hydrogen.
Examples of preferred residues R
2
, R
3
and R
4
are methyl, ethyl, hydroxyethyl and C
3
-C
6
cycloalkyl residues. If one of R
2
, R
3
and R
4
is a cycloalkyl residue, then the other two residues are preferably methyl residues. It is particularly preferred that the residues R
2
, R
3
and R
4
are independently of each other methyl or ethyl residues. It is most preferred when R
2
, R
3
and R
4
are methyl residues so that alkyl phosphocholines represent a particularly preferred class of compounds which is suitable for the production of an agent against protozoal diseases, in particular against leishmaniasis.
It was surprisingly found that compounds having the general formula I when administered orally or topically show no measurable side-effects and a very much higher activity than sodium stibogluconate. In any case the therapeutic agents according to the present invention constitute the first forms of oral therapy for leishmaniasis diseases, and they are considerably more effective than Pentostam, a standard therapeutic preparation used worldwide in the liver and in particular also in the spleen.
In a preferred embodiment of the present invention the oral or topical therapeutic preparation additionally contains one or several alkyl glycerols having the general formula II
in which one of the residues R
6
and R
7
denotes an alkyl group with 2 to 12 C atoms and the other residue denotes a hydrogen atom. An alkyl glycerol mixture is preferably used which contains nonyl or octyl glycerol, hexyl or pentyl glycerol and propyl or ethyl glycerol as well as, if desired, water.
The pharmaceutical agent according to the present invention contains in one dosage unit preferably 5 to 2000 mg, particularly preferably 10 to 500 mg of one or several compounds having the general formula I. For topical administration the pharmaceutical agent according to the present invention preferably contains 5 to 200 mg of one or several compounds having the general formula I per ml of an alkyl glycerol having the formula II or of a corresponding alkyl glycerol mixture.
For oral administration the pharmaceutical agent according to the present invention is preferably formulated as a drinking solution with a daily dosage between 1 and 10 mg/kg of one or several compounds having the general formula I.
The production of an oral pharmaceutical agent according to the present invention can on the other hand also be carried out by mixing or homogenizing one or several compounds having the general formula I with the usual physiologically tolerated filling, carrier, dilution or/and auxiliary substances at temperatures between 20 and 120° C. and, if desired in order to prepare formulations which contain 10 to 800 mg of compounds having the general formula I in one dosage unit, the mixture thus obtained is poured into hollow cells of an appropriate size or filled into capsules of an appropriate size or granulated and then pressed into tablets, if desired, with addition of further common auxiliary substances. The active substance can for example be mixed with one or several of the following auxiliary substances: starch, cellulose, lactose, formalin-casein, modified starch, magnesium stearate, calcium hydrogenphosphate, highly-dispersed silicic acid, talcum and phenoxyethanol. The mixture obtained is granulated, if desired, with an aqueous solution containing for example gelatin, starch, polyvinyl pyrrolidone, vinylpyrrolidon-vinyl acetate copolymerisate or/and polyoxyethylene sobitanmonooleate, as constituent and the granulate is homogenized, if desired, with one or several of the aforementioned auxiliary substances. Subsequently this mixture can be pressed into tablets or filled into capsules whereby the tablets or capsules each contain 10 to 800 mg of active substance in one dosage unit.
In a particularly preferred embodiment the active substance is suspended with soybean lecithin as well as, if desired, 0.1 to 0.5 parts by weight phenoxyethanol (in relation to one part by weight of the active substance) at temperatures between 33 and 37° C. in melted resin fat and homogenized and subseque
Eibl Hansjörg
Engel Jürgen
Unger Clemens
Arent Fox Kintner Plotkin & Kahn
Ghali Isis
Page Thurman K.
Zentaris AG
LandOfFree
Methods of treating protozoal diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating protozoal diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating protozoal diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3041316